Impact of NOD2/CARD15 polymorphisms on response to monoclonal antibody therapy in Crohn’s disease: a systematic review and meta-analysis

References

• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17
   PubMed Web of Science ®Google Scholar
• Tsianos EV, Katsanos KH, Tsianos VE. Role of genetics in the diagnosis and prognosis of Crohn’s disease. World J Gastroenterol 2012;18:105-18
   PubMed Web of Science ®Google Scholar
• Russell RK, Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol 2004;18:525-39
   PubMed Web of Science ®Google Scholar
• Louis E, Collard A, Oger AF, et al. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-82
   PubMed Web of Science ®Google Scholar
• Connelly TM, Messaris E. Predictors of recurrence of Crohn’s disease after ileocolectomy: a review. World J Gastroenterol 2014;20:14393-406
   PubMed Web of Science ®Google Scholar
• Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004;99:2393-404
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 2003;278:5509-12
   PubMed Web of Science ®Google Scholar
• Strober W, Asano N, Fuss I, et al. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn’s disease. Immunol Rev 2014;260:249-60
   PubMed Web of Science ®Google Scholar
• Lakatos L, Mester G, Erdelyi Z, et al. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977–2001. World J Gastroenterol 2004;10:404-9
   PubMed Web of Science ®Google Scholar
• Newman B, Siminovitch KA. Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol 2005;21:401-7
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000
   PubMed Web of Science ®Google Scholar
• Niess JH, Klaus J, Stephani J, et al. NOD2 polymorphism predicts response to treatment in Crohn’s disease – first steps to a personalized therapy. Dig Dis Sci 2012;57:879-86
   PubMed Web of Science ®Google Scholar
• Juanola O, Moratalla A, Gutiérrez A, et al. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease. J Gastroenterol 2015;50:758-68
   PubMed Web of Science ®Google Scholar
• Posovszky C, Pfalzer V, Lahr G, et al. Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn’s disease. BMC Gastroenterol 2013;13:77
   PubMed Web of Science ®Google Scholar
• Weiss B, Lebowitz O, Fidder HH, et al. Response to medical treatment in patients with Crohn’s disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis. Dig Dis Sci 2010;55:1674-80
   PubMed Web of Science ®Google Scholar
• Lu C, Waugh A, Bailey RJ, et al. Crohn’s disease genotypes of patients in remission vs relapses after infliximab discontinuation. World J Gastroenterol 2012;18:5058-64
   PubMed Web of Science ®Google Scholar
• Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn’s disease. Gastroenterology 2002;123:106-11
   PubMed Web of Science ®Google Scholar
• Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn’s disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002;12:509-15
   PubMedGoogle Scholar
• Barreiro-de Acosta M, Ouburg S, Morré SA, et al. NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn’s disease: a preliminary report. Rev Esp Enferm Dig 2010;102:591-5
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-94
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Last Accessed March 2, 2016
   Google Scholar
• Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002
   PubMed Web of Science ®Google Scholar
• Travis SP, Stange EF, Lémann M, et al. European Crohn’s and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006;55(Suppl 1):i16-35
   PubMed Web of Science ®Google Scholar
• Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: Acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroentrol Hepatol 2006;4:1124-9
   Web of Science ®Google Scholar
• Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically-guided dosing. Clin Pharmacokinet 2007;46:187-208
   Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:863-73
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan PG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Naser SA, Arce M, Khaja A, et al. Role of ATG16L, NOD2 and IL23R in Crohn’s disease pathogenesis. World J Gastroenterol 2012;18:412-14
   PubMed Web of Science ®Google Scholar
• Boukercha A, Mesbah-Amroun H, Bouzidi A, et al. NOD2/CARD15 gene mutations in North Algerian patients with inflammatory bowel disease. World J Gastroenterol 2015;21:7786-94
   PubMed Web of Science ®Google Scholar
• Lauriola M, Ugolini G, Rivetti S, et al. IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn’s disease and correlation with sub-phenotypes. Int J Mol Med 2011;27:469-77
   PubMed Web of Science ®Google Scholar
• Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol 2011;106:699-712
   PubMed Web of Science ®Google Scholar
• Solon JG, Burke JP, Walsh SR, Coffey JC. The effect of NOD2 polymorphism on postsurgical recurrence in Crohn’s disease: a systematic review and meta-analysis of available literature. Inflamm Bowel Dis 2013;19:1099-105
   PubMed Web of Science ®Google Scholar
• Coffey JC, O’Leary DP, Kiernan MG, Faul P. The mesentery in Crohn’s disease: friend or foe? Curr Opin Gastroenterol 2016;32:267-73
   PubMed Web of Science ®Google Scholar